Single dose ivabradine <i>versus</i> intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy

Çelik, Ömer; Atasoy, MM; Ertürk, Mehmet; Aa, Yalcin; Aksu, HU; Diker, Mustafa; Aktürk, İF; Atasoy, Işıl

doi:10.1177/0284185113505276

Cited by 9 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although β‐blockers are generally used to achieve short‐term HR reduction during the scan, 16 studies have also investigated ivabradine for this purpose (Table 4). 68–83 One study did not show a benefit of adding single‐dose ivabradine to bisoprolol for additional HR lowering, whereas three studies demonstrated similar HR reduction compared to β‐blockers 70,74,81,82 . One of these studies reported more than twice as many patients treated with ivabradine required additional β‐blockade compared to metoprolol‐treated patients 82 .…”

Section: Resultsmentioning

confidence: 99%

Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults

2020

View full text Add to dashboard Cite

Ivabradine lowers heart rate by inhibiting the hyperpolarization-activated current in pacemaker cells, and its use for the treatment of heart failure (HF) and ischemic heart disease (IHD) is well described. Ivabradine may be an attractive treatment option for other conditions for which a reduction in heart rate is desirable but less is known about its role in these settings. The primary objective was to perform a scoping review summarizing the literature evaluating novel uses for ivabradine other than HF and IHD in adults. PubMed and EMBASE were searched for articles for all dates through September 2019. Search strategies combined terms generic, commercial/trade, and international names for ivabradine. Manual search of references was also performed to identify additional articles. Studies were included if they were published in English, evaluated the efficacy of ivabradine for indications other than HF or IHD in patients aged 18 years or older, and the primary outcome included clinically relevant end points. Articles were screened first by title and abstract followed by full-text screening of the remaining articles. After removal of duplicates, 1807 records were screened for inclusion and 84 studies were included in this scoping review. Novel uses of ivabradine were reported for various tachyarrhythmias, valvular heart disease, premedication for coronary computed tomography angiography, perioperative risk reduction, sepsis with and without multi-organ dysfunction syndrome, cor pulmonale, reactive airway disease, and erectile dysfunction. This scoping review identified several potential novel uses for ivabradine in adults. This review may help to identify existing gaps where further research is needed to elucidate the role of ivabradine for indications beyond HF and IHD. KEY WORDS ivabradine, tachycardia, asthma, CT angiography, perioperative risk reduction, pulmonary hypertension, multi-organ dysfunction syndrome, valvular heart disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults

2020

View full text Add to dashboard Cite

show abstract

“…Additionally, target HR was maintained prior to and during the study. When results were compared to the study by Celik et al 32 , it suggested that greater HR control with IVA was achieved with a twice daily dosing schedule than with a single dose on the day of examination. Pichler et al 36 (n=120) conducted a randomized, prospective, comparative, single blinded trial to evaluate the efficacy of a single oral dose of either 50 mg metoprolol or 15 mg IVA.…”

Section: Major Clinical Trials Testing Ivabradinementioning

confidence: 90%

“…Small randomized control studies have shown superiority of IVA over other drugs in controlling HR 31,32 .…”

Section: Mechanism Of Action Of Ivabradinementioning

confidence: 99%

See 1 more Smart Citation

Lowering of Heart Rate before Computed Tomographic Coronary Angiography: Improvement in Image Quality and Role of Ivabradine

Javed¹,

Hamid²,

Khan³

2015

jcvd

View full text Add to dashboard Cite

Heart rate during coronary computed tomographic angiography (coronary CTA) has a direct correlation with image quality and detection of coronary artery disease. Beta blocking agents are the most commonly used drugs to lower the heart rate, but their use is limited due to adverse effects and contraindications. Ivabradine (IVA) is a novel drug that selectively acts on cardiac pacemaker cells and lowers heart rate. This brief review article emphasizes the importance of slow heart rate for coronary CTA image quality and pre-treatment with IVA as a negative chronotropic agent. We compared the role of other drugs used for this purpose. Keywords -Ivabradine, Coronary CT angiography, Hear rateCite this article as: Javed AA, Hamid MS and Khan MH. Lowering of heart rate before computed tomographic coronary angiography: improvement in image quality and role of ivabradine. JCvD 2015;3(2): 325-329.

show abstract

“…Several authors have proposed pretreatment with ivabradine before coronary CT angiography both in patients that were taking a b blocker or a calcium-channel antagonist [44] and in patients that were not taking anything [45,46]. Results of those studies demonstrated that ivabradine is safe and effective in increasing the rate of patients at the target HR before coronary TC angiography and in reducing the need for additional IV beta-blockade in patients referred for the exam.…”

Section: Pretreatment Before Coronary Ct Angiographymentioning

confidence: 99%

Is There a Role for Ivabradine Beyond its Conventional Use?

Bonadei

Vizzardi

Sciatti

et al. 2014

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy

Abstract: Single dose ivabradine is safe and significantly more effective than i.v. metoprolol in decreasing HR in patients under calcium channel-blocker therapy.

Cited by 9 publications

References 18 publications

Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults

Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults

Lowering of Heart Rate before Computed Tomographic Coronary Angiography: Improvement in Image Quality and Role of Ivabradine

Is There a Role for Ivabradine Beyond its Conventional Use?

Contact Info

Product

Resources

About